MetaCap

Adaptive Biotechnologies Corporation (ADPT)

NASDAQ: ADPTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

27.93-0.12 (-0.43%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ADPT stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.45
52-week range
12.00 – 32.21
Day range
27.15 – 28.23
Volume / Avg
2.48M / 2.20M
Beta
—

52-week range

$12.00$32.21

ADPT stock today

Shares of Adaptive Biotechnologies (ADPT) finished lower on Nov 20 at $27.93, a drop of 0.43% or $0.12 per share, versus the S&P 500's 3.70% decline. Shares are 13.3% below their 52-week high of $32.21, set on Nov 11, 2026 and 132.8% above the 52-week low of $12.00, in the middle of the past year's range. ADPT is up 72.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 50.1%.

Adaptive Biotechnologies has posted a net loss over the last twelve months (EPS of -$0.45), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Adaptive Biotechnologies

Company profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD).

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Chad M. Robins M.B.A.
Headquarters
Seattle, WA
Employees
624
IPO year
2019

Financial highlights

Full financials

In fiscal 2025, Adaptive Biotechnologies generated $277.0 million in revenue, up 54.8% from fiscal 2024, its 2nd consecutive year of revenue growth. Adaptive Biotechnologies reported a net loss of $59.5 million, compared with a loss of $159.5 million a year earlier. Gross margin was 74.2% (up from 59.7%) and operating margin -20.6%.

Adaptive Biotechnologies annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$276.98M$178.96M$170.28M$185.31M$154.34M
Growth+54.77%+5.10%-8.11%+20.06%+56.88%
Net income$-59.50M$-159.49M$-225.25M$-200.19M$-207.28M
EPS (diluted)$-0.39$-1.08$-1.56$-1.40$-1.48

Analyst forecast

Forecast

Consensus (8 analysts)

strong_buy

Avg. price target

$33.86+21.23%

  • Strong buy 2
  • Buy 6
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $30.00High $35.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$0.02 vs $-0.10
Surprise
+120.00%

ADPT news

All ADPT news

Adaptive Biotechnologies peers

Health Care sector
ADPT peer companies
CompanyPrice% ChgMarket capCompare
CRSPCRISPR Therapeutics AG39.10+0.44%$3.79Bvs ADPT
TARSTarsus Pharmaceuticals Inc.73.01-6.00%$3.60Bvs ADPT
RLAYRelay Therapeutics Inc.16.12+1.32%$3.56Bvs ADPT
SRRKScholar Rock Holding Corporation48.13-4.45%$5.87Bvs ADPT
IOVAIovance Biotherapeutics Inc.6.90-5.61%$3.19Bvs ADPT
DNLIDenali Therapeutics Inc.18.45+1.37%$2.96Bvs ADPT
VCELVericel Corporation57.52-1.27%$2.94Bvs ADPT
ADMAADMA Biologics Inc13.17-1.27%$2.92Bvs ADPT

Indexes, lists and sector

Adaptive Biotechnologies stock FAQ

What is Adaptive Biotechnologies's stock price today?

ADPT last traded at $27.93 as of Nov 20, 4:00 PM EST, down 0.43% on the day. Prices are delayed at least 15 minutes.

Who is Adaptive Biotechnologies's CEO?

Mr. Chad M. Robins M.B.A. is the chief executive officer of Adaptive Biotechnologies Corporation, which has about 624 employees.

What is the ADPT 52-week high?

The 52-week high for ADPT is $32.21 and the 52-week low is $12.00. The stock is currently 13.3% below its high.

Compare ADPT